Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIV
NCT ID: NCT01878799
Last Updated: 2016-09-15
Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE2
Total Enrollment
50 participants
Study Classification
INTERVENTIONAL
Study Start Date
2013-06-30
Study Completion Date
2014-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
\- Present treatment for hepatitis C includes the use of a weekly injection and two different pills. This treatment is associated with serious side effects. Drugs that can be taken by mouth and cure HCV infection without serious side effects would be a great help to the large number of people infected with HCV. GS-7977 and GS-5885 are new medications being developed to treat the hepatitis C virus (HCV) infection. They are still being researched and are not approved by the Food and Drug Administration. They are being developed as treatment for hepatitis C as a single pill taken once a day.
Objectives:
\- To determine whether a combination of the two study drugs can safely and effectively treat HCV infection in people with HIV infection and who do not have cirrhosis of the liver.
Eligibility:
\- Individuals who have HIV infection and have liver disease caused by infection with HCV.
Design:
* Participants will be screened with a physical exam and medical history. Blood samples will be collected. Urine samples will be collected from participants who might become pregnant. If a participant has not had a liver biopsy in the past 3 years, one will be required.
* Participants will take one pill daily for 12 weeks. This pill will be a combination of the two study drugs.
* Treatment will be monitored with frequent clinic visits and blood tests over a total of 60 weeks.
\- Present treatment for hepatitis C includes the use of a weekly injection and two different pills. This treatment is associated with serious side effects. Drugs that can be taken by mouth and cure HCV infection without serious side effects would be a great help to the large number of people infected with HCV. GS-7977 and GS-5885 are new medications being developed to treat the hepatitis C virus (HCV) infection. They are still being researched and are not approved by the Food and Drug Administration. They are being developed as treatment for hepatitis C as a single pill taken once a day.
Objectives:
\- To determine whether a combination of the two study drugs can safely and effectively treat HCV infection in people with HIV infection and who do not have cirrhosis of the liver.
Eligibility:
\- Individuals who have HIV infection and have liver disease caused by infection with HCV.
Design:
* Participants will be screened with a physical exam and medical history. Blood samples will be collected. Urine samples will be collected from participants who might become pregnant. If a participant has not had a liver biopsy in the past 3 years, one will be required.
* Participants will take one pill daily for 12 weeks. This pill will be a combination of the two study drugs.
* Treatment will be monitored with frequent clinic visits and blood tests over a total of 60 weeks.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
NCT01817985
Chronic Hepatitis C
COMPLETED
PHASE1
Combination Therapy for Chronic Hepatitis C Infection
NCT01805882
Hepatitis C, Chronic
COMPLETED
PHASE2
Safety and Pharmacokinetics of MK-7680 in Participants With Hepatitis C (MK-7680-003)
NCT02269059
Hepatitis C
COMPLETED
PHASE1
GS-7977 With Ribavirin for Hepatitis C (SPARE)
NCT01441180
Hepatitis C
COMPLETED
PHASE1/PHASE2
Safety, Tolerability, and Antiviral Activity of 24 or 48 Weeks of GS-9190 in Combination With Peginterferon Alfa 2a and Ribavirin for the Treatment of Genotype-1 Chronic HCV Infection
NCT00743795
HCV Infection
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Chronic hepatitis C virus (HCV) infection is a major public health problem with an estimated 180 million people infected worldwide. In the US an estimated 4.1 million people are infected with HCV which is the principal cause of death from liver disease and leading indication for liver transplantation. Significant advances have been made with the approval of directly acting antivirals (DAA) namely the protease inhibitors, telaprevir (TVR) and boceprevir (BOC) which have been shown to significantly improve rates of sustained virologic response (SVR). Response rates to these new combinations in HIV/HCV are also very promising, however treatment has been characterized with high rates of toxicities.
Recently several trials have confirmed the efficacy of potent DAA therapy without concomitant IFN in the treatment of HCV monoinfected individuals. Given the improved response rates achieved with a combination of DAAs with fast HCV suppression and improved side-effect profiles; and the need for better therapy for HIV/HCV co-infected subjects, we propose a study to determine the safety, tolerability and efficacy of 12 weeks of treatment with a fixed dose combination of GS-7977 and GS-5885 in HIV/HCV Genotype 1 (GT-1) subjects. We hypothesize that anti-HCV therapy that does not rely on the host immune system will provide an enhanced rate of SVR among HIV/HCV GT-1 coinfected subjects. The findings from this study will aid in our understanding of determinants of response to an IFN-free regimen in HIV/HCV coinfected individuals.
Recently several trials have confirmed the efficacy of potent DAA therapy without concomitant IFN in the treatment of HCV monoinfected individuals. Given the improved response rates achieved with a combination of DAAs with fast HCV suppression and improved side-effect profiles; and the need for better therapy for HIV/HCV co-infected subjects, we propose a study to determine the safety, tolerability and efficacy of 12 weeks of treatment with a fixed dose combination of GS-7977 and GS-5885 in HIV/HCV Genotype 1 (GT-1) subjects. We hypothesize that anti-HCV therapy that does not rely on the host immune system will provide an enhanced rate of SVR among HIV/HCV GT-1 coinfected subjects. The findings from this study will aid in our understanding of determinants of response to an IFN-free regimen in HIV/HCV coinfected individuals.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Hepatitis C
HIV
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NA
Intervention Model
SINGLE_GROUP
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
HIV
Subjects with HIV and HCV
Group Type
EXPERIMENTAL
GS-7977/GS- 5885 FDC
Intervention Type
DRUG
The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GS-7977/GS- 5885 FDC
The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Eighteen years of age or older at screening.
2. HCV treatment-naive, as defined as no prior exposure to any IFN, RBV, or other approved or experimental HCV-specific direct-acting antiviral agent.
3. Participants must be willing to practice either:
1. Abstinence from sexual intercourse or
2. At least 2 forms of contraception including one barrier method from 2 weeks prior to Day 0 through 30 days after the last dose is received.
i. Female partners of male study subjects may rely upon hormonal contraception as one of the 2 methods; however female study subjects may not.
4. Chronic hepatitis C infection defined as one of the following:
1. Positive for anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening, and positive for HCV RNA and anti-HCV antibody at the time of screening or
2. Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of chronic hepatitis C disease, such as the presence of fibrosis).
5. HIV treatment status:
1. Documented HIV infection, ARV untreated for \> 8 weeks preceding dosing and having either:
1. a CD4 T-cell count greater than or equal to 500 cells/mm3 within 8 weeks of Day 0 or
2. an HIV viral load less than 500 copies/mL with a stable CD4 count for at least 3 months.
2. Documented HIV infection on a stable, protocol-approved, ARV regimen for greater than or equal to 8 weeks prior to dosing and is expected to continue the current ARV regimen through the end of study with all of the following:
1. a CD4 T-cell count \> 100 cells/mm3
2. a documented plasma HIV-1 RNA level less than the level of detection for at least 8 weeks preceding dosing.
If the lower limit of detection of the local HIV-1 RNA assay is \< 50 copies/mL (e.g.,\< 20 copies/mL), the Screening plasma HIV-1 RNA level cannot exceed 50 copies/mL.
3. HIV ARV agents including only combination regimens consisting of medications from the following list: tenofovir (TDF), emtricitabine (FTC), efavirenz, raltegravir, and rilpivirine administered according to their manufacturer s prescribing information. (reference Section 10.3 for additional information)
6. Documentation of hepatitis C genotype 1a, 1b or mixed 1a/1b
7. Absence of cirrhosis, defined as one of the following:
1. A liver biopsy performed within 36 calendar months of screening showing absence of cirrhosis.
2. FibroTest score of \< 0.48 AND APRI of \< 1 performed during the 8 weeks preceding dosing (In the absence of a definitive diagnosis of presence or absence of cirrhosis by the above criteria, a liver biopsy is required).
8. Able to effectively communicate with the Investigator and other center personnel.
9. Willing to give written informed consent and comply with the study restrictions and requirements.
10. If opioid-dependent, subjects must be participating in a supervised treatment.
11. Participants must have a primary medical provider outside of OP8 and the NIH for medical management.
2. HCV treatment-naive, as defined as no prior exposure to any IFN, RBV, or other approved or experimental HCV-specific direct-acting antiviral agent.
3. Participants must be willing to practice either:
1. Abstinence from sexual intercourse or
2. At least 2 forms of contraception including one barrier method from 2 weeks prior to Day 0 through 30 days after the last dose is received.
i. Female partners of male study subjects may rely upon hormonal contraception as one of the 2 methods; however female study subjects may not.
4. Chronic hepatitis C infection defined as one of the following:
1. Positive for anti-HCV antibody, HCV RNA, or an HCV genotype at least 6 months before screening, and positive for HCV RNA and anti-HCV antibody at the time of screening or
2. Positive for anti-HCV antibody and HCV RNA at the time of screening with a liver biopsy consistent with chronic HCV infection (or a liver biopsy performed before enrollment with evidence of chronic hepatitis C disease, such as the presence of fibrosis).
5. HIV treatment status:
1. Documented HIV infection, ARV untreated for \> 8 weeks preceding dosing and having either:
1. a CD4 T-cell count greater than or equal to 500 cells/mm3 within 8 weeks of Day 0 or
2. an HIV viral load less than 500 copies/mL with a stable CD4 count for at least 3 months.
2. Documented HIV infection on a stable, protocol-approved, ARV regimen for greater than or equal to 8 weeks prior to dosing and is expected to continue the current ARV regimen through the end of study with all of the following:
1. a CD4 T-cell count \> 100 cells/mm3
2. a documented plasma HIV-1 RNA level less than the level of detection for at least 8 weeks preceding dosing.
If the lower limit of detection of the local HIV-1 RNA assay is \< 50 copies/mL (e.g.,\< 20 copies/mL), the Screening plasma HIV-1 RNA level cannot exceed 50 copies/mL.
3. HIV ARV agents including only combination regimens consisting of medications from the following list: tenofovir (TDF), emtricitabine (FTC), efavirenz, raltegravir, and rilpivirine administered according to their manufacturer s prescribing information. (reference Section 10.3 for additional information)
6. Documentation of hepatitis C genotype 1a, 1b or mixed 1a/1b
7. Absence of cirrhosis, defined as one of the following:
1. A liver biopsy performed within 36 calendar months of screening showing absence of cirrhosis.
2. FibroTest score of \< 0.48 AND APRI of \< 1 performed during the 8 weeks preceding dosing (In the absence of a definitive diagnosis of presence or absence of cirrhosis by the above criteria, a liver biopsy is required).
8. Able to effectively communicate with the Investigator and other center personnel.
9. Willing to give written informed consent and comply with the study restrictions and requirements.
10. If opioid-dependent, subjects must be participating in a supervised treatment.
11. Participants must have a primary medical provider outside of OP8 and the NIH for medical management.
Exclusion Criteria
1. Current or prior history of any of the following:
1. Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.
2. Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
3. Poor venous access interfering with required study blood collection.
4. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).
5. Solid organ transplantation.
6. Significant pulmonary disease, significant cardiac disease or porphyria.
7. Unstable psychiatric disease (Subjects with psychiatric illness that is well-controlled on a stable treatment regimen or currently not requiring medication may be included).
8. Any malignancy or its treatment that in the opinion of the PI may cause ongoing interference with host immunity; subjects under evaluation for malignancy are not eligible.
9. Significant drug allergy (such as anaphylaxis or hepatotoxicity).
10. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson s disease, alfa-1 antitrypsin deficiency, cholangitis).
11. Patients with renal impairment or uncontrolled medical problems that could place them at high risk for developing renal impairment.
2. Positive test at screening for either HBsAg or quantifiable HBV DNA (completed only if necessary to rule out chronic HBV)
3. Current use of non-protocol approved ARVs.
4. A new AIDS-defining condition diagnosed within 30 days prior to screening or active, serious infection (other than HIV or HCV) requiring parenteral antibiotics, antivirals or antifungals within 30 days prior to Day 0.
5. Cirrhosis of the liver
6. Screening or baseline ECG with clinically significant ECG findings.
7. Abnormal hematological and biochemical parameters, including:
1. Neutrophil count \< 750 cells/mm(3)
2. Hemoglobin \< 9 g/dL. If Hgb is \< 11g/dL in women or \< 12 g/dL in men. Other causes of anemia should be excluded as medically indicated.
3. Platelet count less than or equal to 50,000 cells/mm(3)
4. Estimated GFR (calculated by the CKD-EP(I) equation) \< 50 mL/min/per 1.73 m(2) if not on ARV or \< 60 mL/min if on ARVs
5. ALT or AST greater than or equal to 10 times ULN
6. Serum lipase greater than or equal to 1.5 times ULN (at screening or during the screening period)
7. Direct bilirubin greater than or equal to 1.50 times ULN
8. Albumin less than or equal to 3.0 g/dL
9. INR greater than or equal to 1.5 times ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.
8. Donation or loss of more than 400 mL blood within 8 weeks prior to first dose administration.
9. Poorly controlled diabetes mellitus indicated by hemoglobin A1C \> 10% at screening for known diabetics.
10. Known hypersensitivity to, GS-5885, GS-7977, or formulation excipients.
11. Pregnant/Breastfeeding women.
12. Co-enrollment in other clinical trials is restricted, and requires approval of the Investigator.
Study staff should be notified of co-enrollment status.
13. Need for use of the following medications from 21 days prior to the start of study drugs through the end of treatment:
1. Hematologic stimulating agents (e.g. erythropoiesis-stimulating agents (ESAs); granulocyte colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
2. Chronic systemic immunosuppressants including, but not limited to, corticosteroids (prednisone equivalent of \> 10 mg/day for \> 2 weeks), azathioprine, or monoclonal antibodies (e.g., infliximab)
3. Investigational agents or devices for any indication
4. Medications for disease conditions excluded from the protocol (e.g., active cancer, transplantation) are not listed under this Concomitant Medication section and are disallowed in the study.
5. Concomitant use of certain medications or herbal/natural supplements per PI discretion expected to result in pharmacokinetic interactions resulting in increases or decreases in exposure of study drug(s) as listed in Table of this protocol.
1. Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol; subjects currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.
2. Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
3. Poor venous access interfering with required study blood collection.
4. Clinical hepatic decompensation (i.e., ascites, encephalopathy or variceal hemorrhage).
5. Solid organ transplantation.
6. Significant pulmonary disease, significant cardiac disease or porphyria.
7. Unstable psychiatric disease (Subjects with psychiatric illness that is well-controlled on a stable treatment regimen or currently not requiring medication may be included).
8. Any malignancy or its treatment that in the opinion of the PI may cause ongoing interference with host immunity; subjects under evaluation for malignancy are not eligible.
9. Significant drug allergy (such as anaphylaxis or hepatotoxicity).
10. Chronic liver disease of a non-HCV etiology (e.g., hemochromatosis, Wilson s disease, alfa-1 antitrypsin deficiency, cholangitis).
11. Patients with renal impairment or uncontrolled medical problems that could place them at high risk for developing renal impairment.
2. Positive test at screening for either HBsAg or quantifiable HBV DNA (completed only if necessary to rule out chronic HBV)
3. Current use of non-protocol approved ARVs.
4. A new AIDS-defining condition diagnosed within 30 days prior to screening or active, serious infection (other than HIV or HCV) requiring parenteral antibiotics, antivirals or antifungals within 30 days prior to Day 0.
5. Cirrhosis of the liver
6. Screening or baseline ECG with clinically significant ECG findings.
7. Abnormal hematological and biochemical parameters, including:
1. Neutrophil count \< 750 cells/mm(3)
2. Hemoglobin \< 9 g/dL. If Hgb is \< 11g/dL in women or \< 12 g/dL in men. Other causes of anemia should be excluded as medically indicated.
3. Platelet count less than or equal to 50,000 cells/mm(3)
4. Estimated GFR (calculated by the CKD-EP(I) equation) \< 50 mL/min/per 1.73 m(2) if not on ARV or \< 60 mL/min if on ARVs
5. ALT or AST greater than or equal to 10 times ULN
6. Serum lipase greater than or equal to 1.5 times ULN (at screening or during the screening period)
7. Direct bilirubin greater than or equal to 1.50 times ULN
8. Albumin less than or equal to 3.0 g/dL
9. INR greater than or equal to 1.5 times ULN unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.
8. Donation or loss of more than 400 mL blood within 8 weeks prior to first dose administration.
9. Poorly controlled diabetes mellitus indicated by hemoglobin A1C \> 10% at screening for known diabetics.
10. Known hypersensitivity to, GS-5885, GS-7977, or formulation excipients.
11. Pregnant/Breastfeeding women.
12. Co-enrollment in other clinical trials is restricted, and requires approval of the Investigator.
Study staff should be notified of co-enrollment status.
13. Need for use of the following medications from 21 days prior to the start of study drugs through the end of treatment:
1. Hematologic stimulating agents (e.g. erythropoiesis-stimulating agents (ESAs); granulocyte colony stimulating factor (GCSF); thrombopoietin (TPO) mimetics)
2. Chronic systemic immunosuppressants including, but not limited to, corticosteroids (prednisone equivalent of \> 10 mg/day for \> 2 weeks), azathioprine, or monoclonal antibodies (e.g., infliximab)
3. Investigational agents or devices for any indication
4. Medications for disease conditions excluded from the protocol (e.g., active cancer, transplantation) are not listed under this Concomitant Medication section and are disallowed in the study.
5. Concomitant use of certain medications or herbal/natural supplements per PI discretion expected to result in pharmacokinetic interactions resulting in increases or decreases in exposure of study drug(s) as listed in Table of this protocol.
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Shyamasundaran Kottilil, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999 Aug 19;341(8):556-62. doi: 10.1056/NEJM199908193410802.
Reference Type
BACKGROUND
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006 May 16;144(10):705-14. doi: 10.7326/0003-4819-144-10-200605160-00004.
Reference Type
BACKGROUND
Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002 Nov;36(5 Suppl 1):S30-4. doi: 10.1053/jhep.2002.36791.
Reference Type
BACKGROUND
Townsend K, Petersen T, Gordon LA, Kohli A, Nelson A, Seamon C, Gross C, Tang L, Osinusi A, Polis MA, Masur H, Kottilil S. Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir. AIDS. 2016 Jan;30(2):261-6. doi: 10.1097/QAD.0000000000000903.
Reference Type
DERIVED
Osinusi A, Townsend K, Kohli A, Nelson A, Seamon C, Meissner EG, Bon D, Silk R, Gross C, Price A, Sajadi M, Sidharthan S, Sims Z, Herrmann E, Hogan J, Teferi G, Talwani R, Proschan M, Jenkins V, Kleiner DE, Wood BJ, Subramanian GM, Pang PS, McHutchison JG, Polis MA, Fauci AS, Masur H, Kottilil S. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015 Mar 24-31;313(12):1232-9. doi: 10.1001/jama.2015.1373.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
13-I-0159
Identifier Type: -
Identifier Source: secondary_id
130159
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C
NCT01193478
COMPLETED
PHASE1
GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus
NCT01356160
COMPLETED
PHASE2
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Low-Dose Ribavirin QD in Subjects With Genotype 1a Chronic Hepatitis C Virus Infection
NCT02609659
COMPLETED
PHASE3
Safety, Pharmacokinetics, and Pharmacodynamics of MK-8876 in Participants With Hepatitis C Infection (MK-8876-003)
NCT01930058
COMPLETED
PHASE1
Study to Evaluate the Pharmacokinetics and Safety of GSK2336805 in Subjects With Hepatic Impairment and Healthy Matched Control Subjects
NCT01827657
COMPLETED
PHASE1
Efficacy and Safety Study of GS-9450 Treatment for 6 Months in Patients With Chronic Hepatitis C Virus Infection
NCT00874796
TERMINATED
PHASE2
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Participants With Chronic HCV Infection
NCT01740791
COMPLETED
PHASE1
Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection
NCT01072695
COMPLETED
PHASE2
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
NCT01371578
COMPLETED
PHASE2
Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection
NCT01431898
COMPLETED
PHASE1
A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients
NCT01466790
COMPLETED
PHASE2
Efficacy and Safety of Sofosbuvir Plus Ribavirin in Chronic Genotype 1, 2 and 3 Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infected Adults
NCT01667731
COMPLETED
PHASE3
Safety, Pharmacokinetics, and Pharmacodynamics of MK-6325 in Hepatitis C Virus (HCV) Infections (MK-6325-003)
NCT01329913
COMPLETED
PHASE1
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969
COMPLETED
PHASE2
Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients
NCT00703560
COMPLETED
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection
NCT01316237
COMPLETED
PHASE1
GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype
NCT01384383
TERMINATED
PHASE2
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
NCT00100581
COMPLETED
NA
A First Time in Human Study to Assess GSK2336805 in Healthy Volunteers and Single Doses in Chronically Infected Hepatitis C Patients.
NCT01277692
COMPLETED
PHASE1
Open-Label Hepatic Impairment Study
NCT01497327
COMPLETED
PHASE1
Study of FK788 in Subjects With Chronic Hepatitis C Virus Infection
NCT00047814
COMPLETED
PHASE2
A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C
NCT01591668
COMPLETED
PHASE1
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359
COMPLETED
PHASE1
Safety, Tolerability, and Antiviral Activity of ANA598 in Patients With Genotype-1 Chronic HCV Infection
NCT00782353
COMPLETED
PHASE1